A recent study indicates that individuals who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain shed pounds at a significantly accelerated pace than those who stop conventional lifestyle regimens.
Published data in a leading medical journal points out that while obese people can lose substantial amounts of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing such drugs should be aware of the risk of fast weight regain when the therapy ends," warns researcher Dr. Susan Jebb.
This pace of regain means a return to pre-treatment mass in about a year and a half.
Weighing Therapies
The study, which looked at dozens of trials involving over 9,000 of patients, contrasted the effects of these new drugs with other pills.
Researchers emphasize that individuals who shed pounds through diet and exercise generally have a more gradual weight regain—around 100 grams monthly—after stopping.
Explaining the Fast Rebound
Experts suggest the way of the injections accounts for the heightened regain.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of the hormone levels several times higher than the body's typical production might result in the body to generate a reduced amount of its own natural hormone, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' means appetite is no longer kept in check, making binge eating a significant risk."
An Ongoing Condition?
Health authorities recommend the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals contend that, due to the likelihood of relapse, the therapy is often ongoing.
This opinion is reinforced by drug manufacturers, who note that the results "emphasize the chronic character of excess weight," comparing it to managing diseases like hypertension.
User Accounts
Users who have come off the medication describe a sudden resurgence of cravings.
"I experienced a trigger that goes on and I was suddenly starving," recalled an individual.
The struggle is worsened if individuals have not adopted permanent dietary or behavioural modifications during treatment.
Widespread Interest
Figures show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is greater among women than males.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a magic fix and maintained weight loss relies on combined behavioural changes.
